This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

B. Riley Securities Remains a Buy on OptimizeRx (OPRX)

Tipranks - Tipranks - Thu May 14, 8:44AM CDT

In a report released today, Anderson Schock from B. Riley Securities maintained a Buy rating on OptimizeRx, with a price target of $10.00.

Claim 55% Off TipRanks

Schock covers the Healthcare sector, focusing on stocks such as ClearPoint Neuro, OptimizeRx, and Tactile Systems Technology. According to TipRanks, Schock has an average return of -4.3% and a 50.00% success rate on recommended stocks.

In addition to B. Riley Securities, OptimizeRx also received a Buy from Stifel Nicolaus’s David Grossman in a report issued today. However, on the same day, Stephens assigned a Hold rating to OptimizeRx (NASDAQ: OPRX).

See the top stocks recommended by analysts >>

Based on OptimizeRx’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $32.24 million and a net profit of $5.02 million. In comparison, last year the company earned a revenue of $32.32 million and had a GAAP net loss of $78 thousand

Read More on OPRX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).